Beam Therapeutics Stock
Developer of genome editing technologies.
About Beam Therapeutics Stock
Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.
J. Keith Joung
Chief Scientific Officer
David R. Liu
Co-Founder and Board Member
Chief Executive Officer and Board Member
Wall Streets Journal - Mar, 6 2019
Global University Venturing - May, 15 2018